» Articles » PMID: 37789353

Exosomal MiR-105-5p Derived from Bladder Cancer Stem Cells Targets for GPR12 to Promote the Malignancy of Bladder Cancer

Overview
Journal BMC Urol
Publisher Biomed Central
Specialty Urology
Date 2023 Oct 3
PMID 37789353
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer stem cells (BCSCs) are considered as the root cause of BC initiation and recurrence, and exosomes derived from BCSCs (CSCs-exo) are the vital tool for establishing a stable tumor microenvironment. miR-105-5p has been revealed to promote tumor growth in a variety of cancers, but the effects on BC are still not included.Characteristics of CSCs-exo were examined by transmission electron microscope and nanoparticle tracking analysis. PKH67 dye was used to observe the cellular uptake of exosomes. Cell viability, migration and invasion were detected by CCK-8, wound healing and transwell invasion assays, respectively. The interaction between miR-105-5p and GPR12 was verified by luciferase activity assay. Xenografts were induced in the nude mice, and H&E staining method was applied to analyze the histological changes of xenografts. CSCs-exo efficiently promoted BC cell viability, migration and invasion. miR-105-5p was highly expressed in CSCs and CSCs-exo treatment significantly upregulated the expression of miR-105-5p in BC cells.GPR12 was subsequently verified to be the target gene of miR-105-5p, and overexpression of GPR12 abrogated the effects of miR-105-5p on BC cell growth and metastasis. Reversely, the anti-tumor function of miR-105-5p antagomir was observed in the xenograft mice.CSCs aggravated the malignancy of BC partly through transmitting exosomal miR-105-5p to BC cells to inhibit the expression of GPR12, which developed a novel aspect for CSC-targeted therapies.

Citing Articles

Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host?.

Zou J, Xu B, Luo P, Chen T, Duan H Front Immunol. 2024; 15:1482765.

PMID: 39628486 PMC: 11611751. DOI: 10.3389/fimmu.2024.1482765.


Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.

Zhao J, Ma Y, Zheng X, Sun Z, Lin H, Du C Funct Integr Genomics. 2024; 24(5):147.

PMID: 39217254 DOI: 10.1007/s10142-024-01433-9.


The hidden messengers: cancer associated fibroblasts-derived exosomal miRNAs as key regulators of cancer malignancy.

Gou Z, Li J, Liu J, Yang N Front Cell Dev Biol. 2024; 12:1378302.

PMID: 38694824 PMC: 11061421. DOI: 10.3389/fcell.2024.1378302.

References
1.
Berdik C . Unlocking bladder cancer. Nature. 2017; 551(7679):S34-S35. DOI: 10.1038/551S34a. View

2.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

3.
Prasetyanti P, Medema J . Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017; 16(1):41. PMC: 5314464. DOI: 10.1186/s12943-017-0600-4. View

4.
Beck B, Blanpain C . Unravelling cancer stem cell potential. Nat Rev Cancer. 2013; 13(10):727-38. DOI: 10.1038/nrc3597. View

5.
Zhang J, Li S, Li L, Li M, Guo C, Yao J . Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015; 13(1):17-24. PMC: 4411500. DOI: 10.1016/j.gpb.2015.02.001. View